EMA "road map" calls for more collaborative approach to drug regulation
This article was originally published in Scrip
Executive Summary
The European Medicines Agency (EMA) has outlined a vision of the future EU regulatory environment where regulators and industry start working together earlier on in the drug development process to improve the chances of approval, and information on discontinued drugs is shared with the scientific community to help avoid repetition of studies and reduce the drug development attrition rate.